Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc, a pharmaceutical company incorporated in Ireland, filed this Current Report on Form 8-K on March 1, 2021. The filing announces the release of earnings results for the fourth quarter and the full year ended December 31, 2020. The detailed financial results are contained in the attached press release (Exhibit 99.1), which is not included in the text of this filing.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification of the earnings release rather than a detailed financial statement.
Material Changes and Non-GAAP Adjustments
Management utilizes non-GAAP financial measures to evaluate ongoing operating trends. The filing details specific adjustments made to GAAP results for the periods ended December 31, 2020, and December 31, 2019, to derive these measures. Key adjustments include:
- Exclusions: Amortization of acquired intangible assets, impairment charges, restructuring and separation expenses, acquisition and integration charges, and unusual litigation costs.
- Acquisition/Divestiture Adjustments: Adjustments for net sales related to the Dr. Fresh and Eastern European Brands acquisitions (2020) and the Ranir acquisition (2020). Conversely, results exclude divested businesses such as the animal health business, Canoderm prescription product, and Rosemont Pharmaceuticals.
- Other Items: Changes in financial assets, gains/losses on investment securities and divestitures, foreign currency translation movements, and non-GAAP tax adjustments.
- 2019 Specifics: The 2019 period adjustments also included the impact of the Ranitidine market withdrawal, asset abandonment, and operating results for held-for-sale businesses.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future outlook, or a detailed discussion of risks and contingencies beyond the standard disclosure that non-GAAP measures should be considered in conjunction with GAAP financial statements. The document notes that management uses these adjusted measures for planning, forecasting, and compensation determinations.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific GAAP and non-GAAP financial figures for Q4 and FY 2020.
- Verify the reconciliation between GAAP and non-GAAP measures to understand the magnitude of excluded items like amortization and restructuring charges.
- Assess the impact of the excluded acquisitions (Dr. Fresh, Eastern European Brands) and divestitures on reported organic growth.
- Confirm the status of the Ranitidine market withdrawal and its financial impact as referenced in the 2019 adjustments.